{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:45:22Z","timestamp":1770990322751,"version":"3.50.1"},"reference-count":33,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1185\/030079904x5724","type":"journal-article","created":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T23:17:09Z","timestamp":1107904629000},"page":"1953-1958","source":"Crossref","is-referenced-by-count":16,"title":["Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model"],"prefix":"10.1185","volume":"20","author":[{"given":"Mark B.","family":"Abelson","sequence":"first","affiliation":[{"name":"Ophthalmic Research Associates, North Andover, MA, USA"},{"name":"Schepens Eye Research Institute, Boston, MA, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack V.","family":"Greiner","sequence":"additional","affiliation":[{"name":"Schepens Eye Research Institute, Boston, MA, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2004,11,16]]},"reference":[{"key":"e_1_2_1_2_1","unstructured":"Gilman AG Ral TW Nies AS Taylor P editors Goodman and Gilman\u2019s the pharmacological basis of therapeutics. New York (NY): Pergamon Press 1990"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004397-198802840-00006"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004397-198802840-00017"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(77)90743-7"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(81)90178-1"},{"key":"e_1_2_1_7_1","doi-asserted-by":"crossref","unstructured":"Abelson MB George MA Schefer K Smith LM. Evaluation of the new ophthalmic antihistamine 0.05% levocabastine in the clinical allergen challenge model of allergic conjunctivitis. J Allergy Clin Immunol 1994;94(3 pt1):458\u201364","DOI":"10.1016\/0091-6749(94)90201-1"},{"key":"e_1_2_1_8_1","doi-asserted-by":"crossref","unstructured":"Abelson MB George MA Smith LW. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model. Ophthalmology 1995;102: 310\u20136","DOI":"10.1016\/S0161-6420(95)31023-8"},{"key":"e_1_2_1_9_1","unstructured":"Physicians desk reference for ophthalmic medicines 32nd ed. Medical Economics: Thomson Healthcare 2004 [p. 208\u20139; 289]"},{"key":"e_1_2_1_10_1","unstructured":"Weston JH Udell IJ Abelson MB. H1 receptors in the human ocular surface. Invest Ophthalmol Vis Sci 1981;20(Suppl):32"},{"key":"e_1_2_1_11_1","first-page":"s32","article-title":"diagnosis and management of common ocular allergies","volume":"61","author":"Mechanisms Jennings B.","year":"1990","unstructured":"Jennings B. Mechanisms, diagnosis and management of common ocular allergies. J Am Optom Assoc 1990;61:s32","journal-title":"J Am Optom Assoc"},{"key":"e_1_2_1_12_1","first-page":"57","article-title":"Gleich GJ","volume":"108","author":"Trocme SD","year":"1989","unstructured":"Trocme SD, Kephart GM, Allansmith MR, Bourne WM, Gleich GJ. Conjunctival deposition of eosinophil granule major protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am J Ophthalmol 1989;108:57","journal-title":"Conjunctival deposition of eosinophil granule major protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am J Ophthalmol"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03400200040005"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(86)90119-0"},{"key":"e_1_2_1_15_1","doi-asserted-by":"crossref","unstructured":"Berdy GJ Spangler DL Bensch SS Berdy SS Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther 2000:22: 826\u201333","DOI":"10.1016\/S0149-2918(00)80055-7"},{"key":"e_1_2_1_16_1","first-page":"84","article-title":"Smith L","volume":"108","author":"Abelson MB","year":"1990","unstructured":"Abelson MB, Chambers WA, Smith L. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990;108:84\u20138","journal-title":"Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol"},{"key":"e_1_2_1_17_1","unstructured":"Abelson MB Smith LM. The conjunctival provocation test: a new method for the evaluation of therapeutic agents. Invest Ophthalmol Vis Sci 1988 29(Suppl):45"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1975.01010020978008"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(90)90075-F"},{"key":"e_1_2_1_20_1","first-page":"37","article-title":"Nisson G","volume":"39","author":"Moeller C","year":"1984","unstructured":"Moeller C, Bjorksten B, Nisson G. The precision of the conjunct-ival provocation test. Allergy 1984;39:37","journal-title":"The precision of the conjunct-ival provocation test. Allergy"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(84)90196-5"},{"key":"e_1_2_1_22_1","first-page":"97","article-title":"Bjorksten F","volume":"63","author":"Kari O","year":"1985","unstructured":"Kari O, Salo OP, Bjorksten F. Allergic conjunctivitis, total and specific lgE in the tear fluid. Acta Ophthalmol 1985;63:97","journal-title":"Allergic conjunctivitis, total and specific lgE in the tear fluid. Acta Ophthalmol"},{"key":"e_1_2_1_23_1","doi-asserted-by":"crossref","unstructured":"Sharif NA Xu SX Yanni JM. Olopatadine (AL-4943A) ligand binding and functional studies on a novel long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocul Pharmacol Ther 12(4):1996:401\u20137","DOI":"10.1089\/jop.1996.12.401"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.1996.12.389"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80315-6"},{"key":"e_1_2_1_26_1","first-page":"60","article-title":"An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0","volume":"230","author":"Abelson MB","year":"2000","unstructured":"Abelson MB, Welch DW. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmologica Scandinavica 2000; 230:60\u20133","journal-title":"1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmologica Scandinavica"},{"key":"e_1_2_1_27_1","first-page":"1462","article-title":"Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0","volume":"22","author":"Butrus S","year":"2000","unstructured":"Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2000;22:1462\u201372","journal-title":"1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther"},{"key":"e_1_2_1_28_1","doi-asserted-by":"crossref","unstructured":"Berdy GJ Stoppel JO Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 2002;24: 918\u201329","DOI":"10.1016\/S0149-2918(02)80007-8"},{"key":"e_1_2_1_29_1","doi-asserted-by":"crossref","unstructured":"Spangler Dl Bensch G Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001;23: 1272\u201380","DOI":"10.1016\/S0149-2918(01)80106-5"},{"key":"e_1_2_1_30_1","doi-asserted-by":"crossref","unstructured":"Berdy GJ Spangler DL Bensch G et al. A comparison of the relative efficacy and clinical performance of olopatadine hydro-chloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin Ther 2000;22(7):826\u201333","DOI":"10.1016\/S0149-2918(00)80055-7"},{"key":"e_1_2_1_31_1","first-page":"1227","article-title":"D\u2019Arienzo P, Granet D, Epstein AB, Ledgerwood GL","volume":"20","author":"Lanier BQ","year":"2004","unstructured":"Lanier BQ, Finegold I, D\u2019Arienzo P, Granet D, Epstein AB, Ledgerwood GL. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin 2004;20:1227\u201333","journal-title":"Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin"},{"key":"e_1_2_1_32_1","first-page":"153","article-title":"Petzold U, Ellers-Lenz B","volume":"16","author":"Giede C","year":"2000","unstructured":"Giede C, Metzenauer P, Petzold U, Ellers-Lenz B. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr Med Res Opin 2000;16:153\u201363","journal-title":"Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr Med Res Opin"},{"key":"e_1_2_1_33_1","first-page":"207","article-title":"Bloch Michel E","volume":"8","author":"Richard C","year":"1998","unstructured":"Richard C, Trinquand C, Bloch Michel E. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Eur J Ophthalmol 1998;8:207\u201316","journal-title":"Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Eur J Ophthalmol"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90003-3"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079904X5724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:16:43Z","timestamp":1770387403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079904X5724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11,16]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1185\/030079904X5724"],"URL":"https:\/\/doi.org\/10.1185\/030079904x5724","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11,16]]}}}